Martina Medvedíková

Mrs. Martina Medvedíková

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KBKristyna Burglová
Kristyna Burglová
GRGabriela Rylová
Gabriela Rylová
AMAthanasios Markos
Athanasios Markos
HPHana Prichystalova
Hana Prichystalova
MSMiroslav Soural
Miroslav Soural
JHJan Hlaváč
Jan Hlaváč

21 April 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMMartina Medvedíková
Martina Medvedíková
Václav RancVáclav Ranc
Václav Ranc
JVJan Vanco
Jan Vanco
Zdeněk TrávníčekZdeněk Trávníček
Zdeněk Trávníček
Pavel AnzenbacherPavel Anzenbacher
Pavel Anzenbacher
The effects of two anticancer active copper(II) mixed-ligand complexes of the type [Cu(qui)(mphen)]Y·H2O, where Hqui = 2-phenyl-3-hydroxy- 1H-quinolin-4-one, mphen = bathophenanthroline, and Y = NO3 (complex 1) or BF4 (complex 2) on the activities of different isoenzymes of cytochrome P450 (CYP) have been evaluated. The screening revealed significant inhibitory effects of the complexes on CYP3A4/5 (IC50 values were 2.46 and 4.88 μM), CYP2C9 (IC50 values were 16.34 and 37.25 μM), and CYP2C19 (IC50 values were 61.21 and 77.07 μM). Further, the analysis of mechanisms of action uncovered a non-competitive type of inhibition for both the studied compounds. Consequent studies of pharmacokinetic properties proved good stability of both the complexes in phosphate buffer saline (>96% stability) and human plasma (>91% stability) after 2 h of incubation. Both compounds are moderately metabolised by human liver microsomes (<30% after 1 h of incubation), and over 90% of the complexes bind to plasma proteins. The obtained results showed the potential of complexes 1 and 2 to interact with major metabolic pathways of drugs and, as a consequence of this finding, their apparent incompatibility in combination therapy with most chemotherapeutic agents.

14 May 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMMartina Medvedíková
Martina Medvedíková
JVJan Vanco
Jan Vanco
Zdeněk TrávníčekZdeněk Trávníček
Zdeněk Trávníček
Pavel AnzenbacherPavel Anzenbacher
Pavel Anzenbacher
Background/Objectives: Gold(I) complexes are promising bioactive agents with anticancer and anti-inflammatory potential. This study evaluated cytochrome P450 (CYP) interactions and in vitro pharmacokinetic properties of two Au(I)–triphenylphosphine complexes bearing 6-alkoxy-9-deazapurine ligands. Methods: Complexes [Au(HL1,2)(PPh3)] (HL1 = 6-isopropyloxy-9-deazapurine, complex 1; HL2 = 6-benzyloxy-9-deazapurine, complex 2) were investigated. Inhibition of nine human CYP isoforms was assessed in liver microsomes, and kinetics were analyzed using Dixon and Lineweaver–Burk plots. CYP binding was evaluated by UV–Vis difference spectroscopy. ADME properties (chemical/plasma stability, microsomal stability, plasma protein binding, and PAMPA permeability) were determined. Binding thermodynamics were analyzed by ITC. Results: Both complexes weakly inhibited most CYP isoforms, with stronger effects on CYP2C9 and CYP3A4/5. A non-competitive inhibition mechanism was observed, which may be related to the binding of the complexes to the substrate channels of CYP2C9 and CYP3A4, thereby limiting the active site’s accessibility to the substrate, as supported by molecular docking studies. UV–Vis spectra showed type I binding with Kd values of 9.32 µM (1) and 12.64 µM (2). Both compounds showed high chemical and plasma stability (>90%), moderate microsomal stability (~60% after 60 min), high plasma protein binding (~80%), and low passive permeability. Conclusions: Au(I)–triphenylphosphine complexes with 6-alkoxy-9-deazapurine ligands exhibit moderate CYP affinity and defined pharmacokinetic profiles, supporting further preclinical evaluation.